Topic: Targeted Therapies and Predictive Biomarkers for Breast Cancer

Breast cancer represents the prototypical solid tumor where targets have been identified to enable a personalized approach in systemic therapy. Consequently, biomarkers assume a critical role in guiding precision-targeted treatments. Among the essential biomarkers for breast cancer (BC), estrogen and progesterone receptors have been utilized to select patients suitable for endocrine treatment. Moreover, HER2 status has been analyzed for identifying patients who may gain from antiHER2 therapy. Although methodological problems persist in the determination of predictive biomarkers, new emerging factors such as androgen receptor (AR) have been considered a potential therapeutic target in BC.

To expedite advancements in precision treatment for BC patients, it is imperative to explore additional predictive biomarkers, particularly those that enhance the positive predictive value for endocrine and antiHER2 therapies, as well as biomarkers that predict responses to specific forms of chemotherapy.